Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Hepatitis

Free Subscription Articles published in Gut Retrieve available abstracts of 63 articles: HTML format

Single Articles

March 2026
1. PARLATI L, Bourliere M
   Steatosis severity and metabolic fingerprints after HCV eradication: toward an individualised approach to HCC surveillance after HCV cure.
   Gut. 2026 Mar 11:gutjnl-2026-338140. doi: 10.1136/gutjnl-2026-338140.
   PubMed    
   
   
   
2. HU J, Liu T, Klohn M, Freistaedter A, et al
   Nucleotide analogue bemnifosbuvir inhibits hepatitis E virus replication in preclinical models.
   Gut. 2026 Mar 6:gutjnl-2025-336714. doi: 10.1136/gutjnl-2025-336714.
   PubMed     Abstract available
   
   
   
3. WU W, Gao Q, Hai S, Li X, et al
   Impairment of Rab7-dependent STING degradation hampers HBV replication but accelerates disease progression in chronic hepatitis B comorbid with MASLD.
   Gut. 2026 Mar 3:gutjnl-2026-338065. doi: 10.1136/gutjnl-2026-338065.
   PubMed     Abstract available
   
   
   
4. WENG D, Chen J, Lin C
   Absolute risk stratification of HCC after HCV cure in MASLD: do advanced steatosis and dysglycaemia add beyond liver stiffness?
   Gut. 2026 Mar 2:gutjnl-2026-338294. doi: 10.1136/gutjnl-2026-338294.
   PubMed    
   
   
   February 2026
5. BARTOSCH B, Lauer GM
   Catch me if you can! Is there protection from HCV (re)infection?
   Gut. 2026 Feb 11:gutjnl-2025-337209. doi: 10.1136/gutjnl-2025-337209.
   PubMed    
   
   
   January 2026
6. CORNBERG M, Lampertico P
   Real-world evidence supports earlier treatment in HBeAg-positive but not HBeAg-negative chronic hepatitis B virus infection.
   Gut. 2026 Jan 28:gutjnl-2025-337281. doi: 10.1136/gutjnl-2025-337281.
   PubMed    
   
   
   
7. CHANG YP, Chen YC, Cheng PN, Fang YJ, et al
   Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease.
   Gut. 2026 Jan 20:gutjnl-2025-337275. doi: 10.1136/gutjnl-2025-337275.
   PubMed     Abstract available
   
   
   
8. LIANG X, Luo J, Zhou Q, Xin J, et al
   Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression.
   Gut. 2026;75:367-381.
   PubMed     Abstract available
   
   
   December 2025
9. HE T, Chen M, Liu M, Zhang L, et al
   Twenty-four-week anti-PD-1 antibody regimen promoted HBsAg reduction and concurrently enhanced HBV-specific T cell responses in patients with chronic hepatitis B.
   Gut. 2025 Dec 24:gutjnl-2025-336655. doi: 10.1136/gutjnl-2025-336655.
   PubMed     Abstract available
   
   
   
10. SCHWINGE D
    Hepatocyte guardian: A20 restrains ferroptosis in autoimmune hepatitis.
    Gut. 2025 Dec 24:gutjnl-2025-337347. doi: 10.1136/gutjnl-2025-337347.
    PubMed    
    
    
    
11. LENS S, Burton AR, Davies J, Locatelli M, et al
    Tracking B cell immunity during perturbation of hepatitis B infection induced by treatment withdrawal.
    Gut. 2025 Dec 19:gutjnl-2024-333309. doi: 10.1136/gutjnl-2024-333309.
    PubMed     Abstract available
    
    
    
12. WANG J, Zhang S, Chen Y, Fan T, et al
    Serum thrombospondin-2 as a non-invasive biomarker for liver fibrosis in chronic hepatitis B.
    Gut. 2025 Dec 17:gutjnl-2025-336665. doi: 10.1136/gutjnl-2025-336665.
    PubMed    
    
    
    
13. CHU CM, Liaw YF
    Nucleos(t)ide analogue therapy for EASL immune-tolerant phase hepatitis B.
    Gut. 2025 Dec 3:gutjnl-2025-337558. doi: 10.1136/gutjnl-2025-337558.
    PubMed    
    
    
    November 2025
14. LIN C, Huang Y, Ran N, Liu J, et al
    Therapeutic inhibition of HBsAg and HBV cccDNA through a novel phased combination treatment: glycine and interferon-alpha.
    Gut. 2025;74:2035-2049.
    PubMed     Abstract available
    
    
    
15. CHEN Y, Li W, Wang S, Wang H, et al
    A20-mediated KEAP1 ubiquitination orchestrates hepatocyte ferroptosis to ameliorate autoimmune hepatitis.
    Gut. 2025 Nov 4:gutjnl-2025-336363. doi: 10.1136/gutjnl-2025-336363.
    PubMed     Abstract available
    
    
    
16. KENNEDY PTF, Fung S, Buti M, Yilmaz G, et al
    Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study.
    Gut. 2025 Nov 4:gutjnl-2025-336592. doi: 10.1136/gutjnl-2025-336592.
    PubMed     Abstract available
    
    
    October 2025
17. TANG S, Huang T, Tang R, Lin K, et al
    EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection.
    Gut. 2025 Oct 28:gutjnl-2025-335449. doi: 10.1136/gutjnl-2025-335449.
    PubMed     Abstract available
    
    
    
18. WANG J, Fan T, Zhu L, Zhang S, et al
    Profiles of quantitative hepatitis B surface antigen in patients with chronic hepatitis B.
    Gut. 2025 Oct 23:gutjnl-2025-336924. doi: 10.1136/gutjnl-2025-336924.
    PubMed    
    
    
    
19. CHUMBE AL, van den Aardweg SMD, Boyd A, Grobben M, et al
    Characteristics of an antibody profile associated with protection against hepatitis C virus reinfection in a high-risk cohort.
    Gut. 2025 Oct 23:gutjnl-2025-336302. doi: 10.1136/gutjnl-2025-336302.
    PubMed     Abstract available
    
    
    
20. LIU F, Liu T, Wu X, Yu Z, et al
    iPSC-induced multilineage liver organoids, small intestinal organoids and brain organoids sustain pangenotype hepatitis E virus propagation.
    Gut. 2025 Oct 21:gutjnl-2025-336105. doi: 10.1136/gutjnl-2025-336105.
    PubMed     Abstract available
    
    
    
21. HUANG R, Trinh HN, Yasuda S, Chau A, et al
    Differential HCC risk among HBV indeterminate types at baseline and by phase transition.
    Gut. 2025;74:1873-1882.
    PubMed     Abstract available
    
    
    
22. XU X, Chen J, Yu X, Li Z, et al
    Single-cell analysis identifies RETN(+) monocyte-derived Resistin as a therapeutic target in hepatitis B virus-related acute-on-chronic liver failure.
    Gut. 2025 Oct 6:gutjnl-2025-335998. doi: 10.1136/gutjnl-2025-335998.
    PubMed     Abstract available
    
    
    September 2025
23. TSENG TC, Yang HI, Kao JH
    Reply: Prevalence of serum HBsAg <100 IU/mL in inactive chronic hepatitis B.
    Gut. 2025 Sep 27:gutjnl-2025-336947. doi: 10.1136/gutjnl-2025-336947.
    PubMed    
    
    
    
24. TSENG TC, Yang HI, Kao JH
    Reply to: 'Rethinking "inactive chronic hepatitis B": should we treat patients with high HBsAg levels?'.
    Gut. 2025 Sep 27:gutjnl-2025-336618. doi: 10.1136/gutjnl-2025-336618.
    PubMed    
    
    
    August 2025
25. FAN T, Wang J, Zhu C, Wu C, et al
    Prevalence of serum HBsAg <100 IU/mL in inactive chronic hepatitis B.
    Gut. 2025 Aug 24:gutjnl-2025-336520. doi: 10.1136/gutjnl-2025-336520.
    PubMed    
    
    
    
26. SU CW, Liang YJ, Wu JC
    Unravelling the heterogeneous HCC risk in indeterminate chronic hepatitis B.
    Gut. 2025 Aug 18:gutjnl-2025-335915. doi: 10.1136/gutjnl-2025-335915.
    PubMed    
    
    
    
27. WU X, Quan D, Li W, Wisskirchen K, et al
    Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial.
    Gut. 2025 Aug 12:gutjnl-2025-335456. doi: 10.1136/gutjnl-2025-335456.
    PubMed     Abstract available
    
    
    
28. HUI RW, Wu TK, Ho KC, Leung RH, et al
    Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure.
    Gut. 2025 Aug 5:gutjnl-2025-335219. doi: 10.1136/gutjnl-2025-335219.
    PubMed     Abstract available
    
    
    July 2025
29. SETO WK, Lok A
    Partial cure of chronic hepatitis B: potential implications for HCC surveillance?
    Gut. 2025 Jul 29:gutjnl-2025-336032. doi: 10.1136/gutjnl-2025-336032.
    PubMed    
    
    
    
30. CHEN J, You H, Lau G
    Rethinking 'Inactive Chronic Hepatitis B': should we treat patients with high HBsAg levels?
    Gut. 2025 Jul 23:gutjnl-2025-336373. doi: 10.1136/gutjnl-2025-336373.
    PubMed    
    
    
    
31. GUILLOT A, Pose E
    Hepatocyte senescence in alcohol-associated hepatitis: epiphenomenon or disease-driving mechanism?
    Gut. 2025 Jul 17:gutjnl-2025-335271. doi: 10.1136/gutjnl-2025-335271.
    PubMed    
    
    
    June 2025
32. TSENG TC, Huang SC, Pan MH, Liu CJ, et al
    Hepatitis B surface antigen level identifies patients with inactive chronic hepatitis B from Asia with HCC risk below surveillance threshold.
    Gut. 2025 Jun 20:gutjnl-2025-334911. doi: 10.1136/gutjnl-2025-334911.
    PubMed     Abstract available
    
    
    May 2025
33. LI H, Song M, Hylemon PB, Zhou H, et al
    LECT2-PHB2 axis: a new mechanistic insight and therapeutic opportunity in alcohol-associated hepatitis.
    Gut. 2025 May 13:gutjnl-2025-335259. doi: 10.1136/gutjnl-2025-335259.
    PubMed    
    
    
    April 2025
34. ROTTELE F, Zollner A, Mogler C, Yuksel M, et al
    Characteristic immune cell interactions in livers of children with acute hepatitis revealed by spatial single-cell analysis identify a possible postacute sequel of COVID-19.
    Gut. 2025 Apr 5:gutjnl-2024-333880. doi: 10.1136/gutjnl-2024-333880.
    PubMed     Abstract available
    
    
    
35. LURJE I, Tacke F
    Immune pathology in paediatric acute hepatitis of unknown origin - uncovering the link to COVID-19.
    Gut. 2025 Apr 5:gutjnl-2024-334453. doi: 10.1136/gutjnl-2024-334453.
    PubMed    
    
    
    
36. GLEESON D, Bornand R, Brownlee A, Dhaliwal H, et al
    British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis.
    Gut. 2025 Apr 1:gutjnl-2024-333171. doi: 10.1136/gutjnl-2024-333171.
    PubMed     Abstract available
    
    
    March 2025
37. XU H, Wu Z, Qin J, Li X, et al
    Stressed hepatocyte sustains alcohol-associated hepatitis progression by producing leukocyte cell-derived chemotaxin 2.
    Gut. 2025 Mar 26:gutjnl-2024-334318. doi: 10.1136/gutjnl-2024-334318.
    PubMed     Abstract available
    
    
    
38. RODRIGO-TORRES D, Kilpatrick AM, Ferreira-Gonzalez S, Aird RE, et al
    Longitudinal paired liver biopsies and transcriptome profiling in alcohol-associated hepatitis reveal dynamic changes in cellular senescence.
    Gut. 2025 Mar 23:gutjnl-2024-334094. doi: 10.1136/gutjnl-2024-334094.
    PubMed     Abstract available
    
    
    December 2024
39. LAMPERTICO P, Anolli MP, Roulot D, Wedemeyer H, et al
    Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies.
    Gut. 2024 Dec 11:gutjnl-2024-332597. doi: 10.1136/gutjnl-2024-332597.
    PubMed     Abstract available
    
    
    October 2024
40. PAN DZ, Soulette CM, Aggarwal A, Han D, et al
    Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B.
    Gut. 2024 Oct 8:gutjnl-2024-332526. doi: 10.1136/gutjnl-2024-332526.
    PubMed     Abstract available
    
    
    
41. LIU T, Li J, Yin X, Lu F, et al
    Establishment of enterically transmitted hepatitis virus animal models using lipid nanoparticle-based full-length viral genome RNA delivery system.
    Gut. 2024 Oct 1:gutjnl-2024-332784. doi: 10.1136/gutjnl-2024-332784.
    PubMed     Abstract available
    
    
    September 2024
42. BROL MJ, Canbay A, Trebicka J
    Alcohol-associated hepatitis: a neutrophile disease?
    Gut. 2024 Sep 24:gutjnl-2024-333222. doi: 10.1136/gutjnl-2024-333222.
    PubMed    
    
    
    
43. MAK LY, Wooddell CI, Lenz O, Schluep T, et al
    Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989.
    Gut. 2024 Sep 12:gutjnl-2024-333026. doi: 10.1136/gutjnl-2024-333026.
    PubMed     Abstract available
    
    
    
44. FAN R, Zhao S, Niu J, Ma H, et al
    High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy.
    Gut. 2024;73:1725-1736.
    PubMed     Abstract available
    
    
    July 2024
45. VECCHI A, Rossi M, Tiezzi C, Fisicaro P, et al
    HBcrAg values may predict virological and immunological responses to pegIFN-alpha in NUC-suppressed HBeAg-negative chronic hepatitis B.
    Gut. 2024 Jul 20:gutjnl-2024-332290. doi: 10.1136/gutjnl-2024-332290.
    PubMed     Abstract available
    
    
    
46. KREIMEYER H, Gonzalez CG, Fondevila MF, Hsu CL, et al
    Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis.
    Gut. 2024 Jul 20:gutjnl-2024-332730. doi: 10.1136/gutjnl-2024-332730.
    PubMed     Abstract available
    
    
    
47. BAUMERT T, Urbanek-Quaing M, Cornberg M
    Immunomodulation and entry inhibition: selgantolimod's double punch against hepatitis B virus.
    Gut. 2024 Jul 5:gutjnl-2024-332679. doi: 10.1136/gutjnl-2024-332679.
    PubMed    
    
    
    
48. KAMAR N, Marion O, Abravanel F, Esposito L, et al
    Porcine-derived pancreatic enzyme replacement therapy: a cause of hepatitis E virus transmission?
    Gut. 2024 Jul 2:gutjnl-2024-332744. doi: 10.1136/gutjnl-2024-332744.
    PubMed    
    
    
    June 2024
49. ZHOU J, Liu K, Pan Q
    Porcine-derived pancreatic enzyme replacement therapy linking to chronic hepatitis E: broad implications.
    Gut. 2024 Jun 12:gutjnl-2024-332975. doi: 10.1136/gutjnl-2024-332975.
    PubMed    
    
    
    May 2024
50. FRERICKS N, Kinast V, Steinmann E
    Potential risk of porcine-derived pancreatic enzyme medication for the cross-species transmission of hepatitis E virus.
    Gut. 2024 May 31:gutjnl-2024-332577. doi: 10.1136/gutjnl-2024-332577.
    PubMed    
    
    
    
51. VO-QUANG E, Pawlotsky JM
    'Unusual' HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment.
    Gut. 2024 May 23:gutjnl-2024-332177. doi: 10.1136/gutjnl-2024-332177.
    PubMed     Abstract available
    
    
    
52. ROCA SUAREZ AA, Plissonnier ML, Grand X, Michelet M, et al
    TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism.
    Gut. 2024 May 2:gutjnl-2023-331396. doi: 10.1136/gutjnl-2023-331396.
    PubMed     Abstract available
    
    
    April 2024
53. THORNTON CS, Waddell BJ, Congly SE, Svishchuk J, et al
    Porcine-derived pancreatic enzyme replacement therapy may be linked to chronic hepatitis E virus infection in cystic fibrosis lung transplant recipients.
    Gut. 2024 Apr 15:gutjnl-2023-330602. doi: 10.1136/gutjnl-2023-330602.
    PubMed     Abstract available
    
    
    January 2024
54. HE T, Zhang D
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B: still needs further discussion.
    Gut. 2024 Jan 22:gutjnl-2023-331443. doi: 10.1136/gutjnl-2023-331443.
    PubMed    
    
    
    
55. 
    Correction: Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies.
    Gut. 2024;73:e1.
    PubMed    
    
    
    
56. LIN C, Luo L, Xun Z, Zhu C, et al
    Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection.
    Gut. 2024;73:338-349.
    PubMed     Abstract available
    
    
    November 2023
57. WANG Y, Li Q, Li C, Wang C, et al
    Chimeric antigen receptors of HBV envelope proteins inhibit hepatitis B surface antigen secretion.
    Gut. 2023 Nov 16:gutjnl-2023-330537. doi: 10.1136/gutjnl-2023-330537.
    PubMed     Abstract available
    
    
    
58. YU X, Gong Q, Yu D, Chen Y, et al
    Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss.
    Gut. 2023 Nov 15:gutjnl-2023-330577. doi: 10.1136/gutjnl-2023-330577.
    PubMed     Abstract available
    
    
    October 2023
59. TESTONI B, Scholtes C, Plissonnier ML, Paturel A, et al
    Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B.
    Gut. 2023 Oct 25:gutjnl-2023-330644. doi: 10.1136/gutjnl-2023-330644.
    PubMed     Abstract available
    
    
    
60. CHOI WM, Kim GA, Choi J, Choi GH, et al
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Gut. 2023 Oct 9:gutjnl-2023-330225. doi: 10.1136/gutjnl-2023-330225.
    PubMed     Abstract available
    
    
    
61. LIU Z, Lin C, Mao X, Guo C, et al
    Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people.
    Gut. 2023 Oct 5:gutjnl-2023-330691. doi: 10.1136/gutjnl-2023-330691.
    PubMed     Abstract available
    
    
    September 2023
62. LE BERT N, Fisicaro P
    Enolase: a metabolic checkpoint behind diverse exhaustion stages of CD8+ T cells in chronic HBV and HCV.
    Gut. 2023 Sep 6:gutjnl-2023-330541. doi: 10.1136/gutjnl-2023-330541.
    PubMed    
    
    
    January 2023
63. HENDRIKX T, Lang S, Rajcic D, Wang Y, et al
    Hepatic pIgR-mediated secretion of IgA limits bacterial translocation and prevents ethanol-induced liver disease in mice.
    Gut. 2023 Jan 23:gutjnl-2022-328265. doi: 10.1136/gutjnl-2022-328265.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum